Buying, Selling, and Change of Ownership: What Actually Happens on the Licensing Side

By Chase Wilson, Pharm.D., and Allyson Snow, J.D.

Most people picture a pharmacy change of ownership as one obvious event: someone builds a pharmacy, decides to exit, and sells the whole thing. That version is real, and it does trigger a change of ownership everywhere the pharmacy is licensed. But the licensing consequences of a change of ownership are not limited to that scenario, and they are not limited to pharmacies operating in all fifty states either. A pharmacy licensed in only two or three states runs into the same underlying complexity as one licensed nationally, because the complexity comes from how ownership itself is defined, not from how many states are involved. New investment coming in, a new partner joining, a piece of equity changing hands quietly at the upper levels of ownership, any of these can trigger a change of ownership under a given state’s rules, whether anyone at the pharmacy level realizes it happened.

This piece walks through what counts as a change of ownership, why the licensing side of a change of ownership is more involved than most people expect, and what a pharmacy or buyer can do now to avoid some of the more common and more costly mistakes.

What Actually Counts as a Change of Ownership

The obvious triggers are the ones everyone already plans for: a full sale, a merger, an owner exiting the business entirely. Where pharmacies get into trouble is with the quieter version. Many states set a threshold above which a transfer of equity constitutes a change of ownership, even if the pharmacy itself keeps operating under the same name, in the same location, with the same staff. A new investor coming in, a new partner being added, a restructuring at the ownership level that never touches day-to-day operations, all of these can cross that threshold depending on the state.

The reason this causes real problems is that this kind of change is often only disclosed at the ownership or C-suite level and never trickles down to the people filing the pharmacy’s renewals. A pharmacist in charge filling out a routine license renewal will attest that there has been no change of ownership, in good faith, because as far as they know, nothing has changed. Meanwhile, a minority equity transfer at the grandparent or great-grandparent level may have already triggered a reportable change of ownership in several of the pharmacy’s licensed states. That gap can sit unnoticed for years before it surfaces, and once it does, the pharmacy is not just late on one filing, it is untimely across every state where that threshold was crossed and never reported.

The practical takeaway is simple to state and easy to miss in practice: any change in beneficial ownership, no matter how far removed it feels from pharmacy operations, is worth flagging and checking against your specific states’ definitions before it happens, not after.

How We Approach a Sale or Purchase

We use a three-step approach for any sale or purchase, and it is worth walking through what each step looks like in the context of a sale or purchase.

The first step is gathering everything up front: identifying which of the pharmacy’s licensed states will treat this specific transaction as a reportable change of ownership, and what each of those states requires to report it. Each transaction is different, and reporting could depend on the transaction type, whether it is a stock or asset purchase, how the previous ownership was reported to the board of pharmacy, and what level of ownership the transaction is occurring at.

The second step is submitting what each state requires, and this is where change of ownership starts to look meaningfully different from something like a pharmacist-in-charge change. With a pharmacist-in-charge change, very few states want notice before the change takes effect. With a change of ownership, a substantial share of states require notice or a completed application before the transaction closes, not after. That single difference changes the entire timeline of a deal, because licensing can no longer be treated as a post-closing cleanup task. It must be built into the closing timeline itself. The DEA and other registrations pertinent to the business (NPI, NCPDP, accreditations) have their own notice requirements and the sequencing must be integrated into the project plan as well.

The third step is tracking each of those filings to completion and handling deficiencies as they come in, which, depending on the state and the complexity of the ownership structure involved, can turn into a significant project on its own.

Identifying No-Ship States

In some states, the pharmacy has to have its new license fully issued before the new owner can legally ship or dispense medication under that ownership. This is a good example of how one licensing detail, easy to overlook while everyone is focused on the deal itself, can trip up an otherwise well-planned transaction and stop it cold. If the closing happens before that license is in hand, the pharmacy cannot fill prescriptions in that state until it is. If that state happens to be a large part of the pharmacy’s patient base, that is not a paperwork delay, it is a business interruption, and it generally falls to the new owner the day after closing, depending on how the transaction documents allocate that risk.

Avoiding that means working backward from each license-dependent state’s timeline when the deal is being structured, not forward from the signing date. Continuity of care, making sure patients do not lose access to their medication through the transition, must be a closing condition built into the deal itself, not something addressed after the fact.

The Paperwork Is Still, Genuinely, Paper

It is easy to assume that everything now runs through an online portal. It does not. Some states still require physical applications, mailed in, and the volume can be substantial. Regardless of submission type, applications have become increasingly longer, more complex and require more detailed information about the applicant, officers and staff, particularly pharmacies with complex ownership structures.

California is a useful example of why deficiencies get more complicated as ownership structures get more complex. A deficiency response there is often not about something missing from the application itself. It more often reflects additional questions about the ownership structure itself, including the pharmacy’s operating agreement, questions that are less likely to arise with a simpler ownership structure. Deficiency responses in matters involving layered ownership can become substantial documents, and they often must be assembled on a short timeline. The more complex the ownership, the more scrutiny the application may draw, and the more time it is worth building into the timeline. With this complexity, and California’s requirement that the new license be issued before the new owner can dispense into the state, the status of the California application should play an integral part in choosing the closing date of the transaction.

What You Can Actually Do About This Now

None of this needs to be overwhelming, and there are two concrete steps worth taking regardless of where your pharmacy stands today.

First, before any change in investment, ownership, or partnership structure, however small it seems, check it against the actual change-of-ownership threshold in every state where your pharmacy is licensed. Do not rely on whether the change feels significant at the operating level. The states are working from their own legal definitions, not your internal sense of what qualifies as a big deal.

Second, if you are structuring a purchase or sale, build the closing timeline around your state’s licensing requirements rather than fitting licensing into a timeline that has already been set. Identify early which states require notice before closing and which ones require a license in hand before the new owner can dispense and treat those dates as hard constraints on the deal itself.

Those two steps can surface many of the problems that otherwise turn into trouble later. Where this tends to outgrow what one or two internal actions can handle is exactly where the detail lives: state-by-state ownership definitions that do not match each other, paperwork that is still genuinely paper, and sequence with agencies like the DEA. That is the point where it is worth involving counsel with experience in handling these filings in multiple jurisdictions. If your pharmacy is planning a transaction or trying to work out whether some percentage change in ownership at some level of the ownership structure should have been reported, that is the kind of project our licensing team works through with pharmacies and buyers.